Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. TTK Healthcare's Revenue for the
three
months ended in Jun. 2026 was ₹2,576 Mil. TTK Healthcare's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹1,107 Mil.
Hence, TTK Healthcare's Receivables Turnover for the
three
months ended in Jun. 2026 was 2.33.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
TTK Healthcare Receivables Turnover Related Terms
TTK Healthcare Receivables Turnover Historical Data
* Premium members only.
The historical data trend for TTK Healthcare's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:507747 vs LLY, JNJ, ABBV: Receivables Turnover Comparison
For the Drug Manufacturers - General subindustry, TTK Healthcare's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TTK Healthcare Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TTK Healthcare's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where TTK Healthcare's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TTK Healthcare (BOM:507747) has a Receivables Turnover of 2.33 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on TTK Healthcare and its competitors. According to the industry distribution chart, TTK Healthcare ranks #182 out of 947 companies in the Drug Manufacturers industry, placing it in the top 19.2%.
Is TTK Healthcare's Receivables Turnover too high?
TTK Healthcare's current Receivables Turnover is 2.33. The Drug Manufacturers industry median Receivables Turnover is 5.08. TTK Healthcare's value of 2.33 is 54.1% below this industry median. Based on the distribution chart, TTK Healthcare ranks #182 out of 947 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, TTK Healthcare has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTK Healthcare's Receivables Turnover compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, TTK Healthcare ranks #182 out of 947 companies for Receivables Turnover. This places TTK Healthcare in the top 19% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.08. TTK Healthcare's value of 2.33 is 54.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.08, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TTK Healthcare's current Receivables Turnover of 2.33 is 54.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on TTK Healthcare and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TTK Healthcare's current Receivables Turnover is 2.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTK Healthcare stock overvalued right now?
Based on GuruFocus' analysis, TTK Healthcare (BOM:507747) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,440.94, compared to a current price of ₹1,135.55 — trading 21.2% below its estimated fair value. The current Receivables Turnover is 2.33 and 54.1% below the Drug Manufacturers industry median of 5.08. TTK Healthcare's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For TTK Healthcare (BOM:507747), the current Receivables Turnover is 2.33 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TTK Healthcare (BOM:507747) Overvalued in 2026?
Based on GuruFocus' analysis, TTK Healthcare stock appears to be undervalued.
The current stock price of ₹1,135.55 is trading 21.2% below its estimated GF Value™ of ₹1,440.94.
GuruFocus considers TTK Healthcare to be Modestly Undervalued.
Key valuation signals for BOM:507747:
Receivables Turnover: 2.33
GF Value™: ₹1,440.94 vs. price of ₹1,135.55 (21.2% below fair value)
Industry Position: 54.1% below the Drug Manufacturers median (#182 of 947)
No single metric tells the full story. See the BOM:507747 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TTK Healthcare Ltd is an Indian pharmaceutical company. The company's operating segment includes Animal Welfare, Consumer Products, Medical Devices, Protective Devices, Foods Division, and Others. Its Animal Welfare segment includes products for both Human and Veterinary use. The Consumer Products comprises of marketing and distribution of Woodwards's Gripe Water, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Fresheners and others. Protective Devices comprises of manufacturing and marketing of Male Contraceptives and other allied products. It generates maximum revenue from the Pharmaceuticals segment. Geographically, it derives a majority of revenue from India.
77GF Score
Get the complete analysis for BOM:507747
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:507747 has been successfully added to your 
